

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic  
substances identified in English-, French-, German-,  
and Japanese-language basic patents from 2004-present  
NEWS 3 NOV 26 MARPAT enhanced with FSORT command  
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 5 NOV 26 Two new SET commands increase convenience of STN  
searching  
NEWS 6 DEC 01 ChemPort single article sales feature unavailable  
NEWS 7 DEC 12 GBFULL now offers single source for full-text  
coverage of complete UK patent families  
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS  
NEWS 9 JAN 06 The retention policy for unread STNmail messages  
will change in 2009 for STN-Columbus and STN-Tokyo  
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent  
Classification Data  
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added  
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE  
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING  
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE  
NEWS 14 FEB 10 COMPENDEX reloaded and enhanced  
NEWS 15 FEB 11 WTEXTILES reloaded and enhanced  
  
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:07:39 ON 12 FEB 2009

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 09:07:50 ON 12 FEB 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 FEB 2009 HIGHEST RN 1104680-36-5  
DICTIONARY FILE UPDATES: 11 FEB 2009 HIGHEST RN 1104680-36-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10596500.str



chain nodes :

10 18 19 22

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16

chain bonds :

8-18 9-10 10-11 18-19 18-22

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15  
15-16

exact/norm bonds :

2-7 3-9 7-8 8-9 8-18 9-10 18-19 18-22

exact bonds :

10-11  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16  
 isolated ring systems :  
 containing 1 : 11 :

G1: Ak, H

G2: Cb, Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 Ak, H

G2 Cb, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 09:08:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS

30 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 2671 TO 4249

PROJECTED ANSWERS: 272 TO 928

L2 30 SEA SSS SAM L1

=> s 11 sss full

FULL SEARCH INITIATED 09:08:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3704 TO ITERATE


100.0% PROCESSED 3704 ITERATIONS  
SEARCH TIME: 00.00.01

470 ANSWERS

L3 470 SEA SSS FUL L1

=> d scan


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 3-Pyridinol, 2-[[5,7-dimethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-  
1H-benzimidazol-1-yl]methyl]-6-methyl-  
MF C24 H34 N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):40


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 3-Pyridinol, 6-methyl-2-[[2-[[2-(3-methylphenyl)ethyl]amino]-1H-  
benzimidazol-1-yl]methyl]-  
MF C23 H24 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Acetamide, N-[6-formyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-

1H-benzimidazol-2-yl]-  
MF C24 H22 N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]-  
MF C20 H25 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 1H-Benzimidazol-2-amine, 6-(chloromethyl)-1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-N-[3-(4-morpholinyl)propyl]-  
MF C23 H30 Cl N5 O2  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Carbamic acid, [2-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI)  
 MF C37 H51 N7 O4





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]-  
 MF C23 H31 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-  
 MF C21 H27 N5 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-6-methanamine, N-(2,5-dimethylphenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-  
 MF C30 H38 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-6-methanamine, 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-  
 N-[2-[2-(4-morpholinyl)ethyl]phenyl]-2-[[3-(4-morpholinyl)propyl]amino]-  
 MF C35 H47 N7 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-  
 [[3-(4-thiomorpholinyl)propyl]amino]-  
 MF C22 H29 N5 O2 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[6-[(2,3-dihydro-6-methyl-1H-indol-1-yl)methyl]-2-[[3-(4-  
 morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 MF C31 H38 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)-2-pyrimidinylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 MF C28 H36 N8 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Propanamide, 3-[(3-ethynylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-  
 MF C33 H39 N7 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Butanamide, 4-[(4-cyanophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-  
 MF C33 H40 N8 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-  
 pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-  
 yl]methyl]amino]-N-methyl-  
 MF C35 H47 N7 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-  
 [[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 MF C32 H42 N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[6-[[[2-[(2-hydroxyethyl)amino]-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 MF C31 H41 N7 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[6-[[[2-(4-hydroxybutyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 MF C33 H44 N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-6-carboxaldehyde,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(1-  
 piperidinyl)propyl]amino]-  
 MF C23 H29 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(1-  
 piperidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 MF C31 H40 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[2-[(3-hydroxypropyl)amino]-1H-benzimidazol-1-yl]methyl]-6-  
 methyl-  
 MF C17 H20 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[2-[[4-(2-aminoethyl)phenyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 MF C24 H27 N5 O  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzamide, 4-fluoro-N-[1-[2-(2-pyridinyl)ethyl]-5-(trifluoromethyl)-1H-benzimidazol-2-yl]-  
 MF C22 H16 F4 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C33 H32 N6 O3


Cc1cc(C)cc(NCCc2ccccc2N=C(NC(C)C)NCCc3cc(O)c(C)cn3)c1

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Cc1cc(C)c2c(c1)nc(NC(=O)CCCC)c2CNc3cc(O)c(C)cn3


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Acetamide, N-[6-[[ (2,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]-  
 MF C25 H27 N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]-2-oxo-, inner salt  
 MF C30 H34 N8 O3




L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 MF C22 H28 Cl N5 O2  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-6-methanol, 1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-  
 MF C21 H26 Br N5 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-5-methanol, 2-[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel-  
 MF C24 H33 N5 O3


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenepropanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]amino]-4-methyl-  
 MF C33 H44 N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzamide, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-  
 MF C30 H37 N7 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-  
 MF C31 H40 N6 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-6-methanol, 2-[[3-[(2R,6R)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel-  
 MF C24 H33 N5 O3

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1-Propanesulfonamide, 3-[[4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3,5-dimethylphenyl]amino]-, hydrochloride (1:?)  
 MF C33 H45 N7 O4 S . x Cl H




● x HCl

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(2-methyl-5-(1-methylethyl)phenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 MF C34 H46 N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(2-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 MF C31 H40 N6 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1-Butanesulfonamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]-  
 MF C33 H45 N7 O4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN  $\beta$ -Alanine, N-(3,5-dimethylphenyl)-N-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-, ethyl ester  
 MF C35 H46 N6 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

186.84

187.06

FILE 'CAPLUS' ENTERED AT 09:09:36 ON 12 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Feb 2009 VOL 150 ISS 7  
FILE LAST UPDATED: 11 Feb 2009 (20090211/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 09:07:39 ON 12 FEB 2009)

FILE 'REGISTRY' ENTERED AT 09:07:50 ON 12 FEB 2009

L1 STRUCTURE UPLOADED  
L2 30 S L1  
L3 470 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:09:36 ON 12 FEB 2009

=> s 13

L4 16 L3

=> s 13 and (pry<2004)

16 L3  
4266527 PRY<2004  
L5 7 L3 AND (PRY<2004)

=> s 13

L6 16 L3

=> d 1-16 ibib abs hitstr

L6 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1508519 CAPLUS

DOCUMENT NUMBER: 150:56153

TITLE: Benzimidazole derivatives and related compounds for inhibiting KSP kinesin activity and their preparation and use in the treatment of KSP-associated diseases  
INVENTOR(S): Shipps, Gerald W., Jr.; Ma, Yao; Lahue, Brian Robert; Seghezzi, Wolfgang; Herbst, Ronald; Chuang, Cheng-Chi; Annis, D. Allen; Kirtley, Matthew

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 319pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2008153701	A1	20081218	WO 2008-US6472	20080521
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:



US 2007-939963P

P 20070524

OTHER SOURCE(S):

MARPAT 150:56153

GI




AB The invention provides compds. of formula I as KSP kinesin inhibitors. The invention also provides compns. comprising these compds. that are useful for treating cellular proliferative diseases or disorders associated with KSP kinesin activity and for inhibiting KSP kinesin activity. Compds. of formula I wherein R is H, (halo)alkyl, CN, halo, SH and derivs., etc.; R1 is alkyl, heterocyclyl, aroyl, NH2 and derivs., etc.; R2 and R3 are independently H, alkyl and (un)substituted methylene; R4 is alkyl, (un)substituted cycloalkyl, (un)substituted heterocyclyl, and (un)substituted (hetero)aryl; and pharmaceutically acceptable salts, solvates and esters thereof, are claimed. Example compound II was prepared by a general solid phase procedure (procedure given). All the invention compds. were evaluated for their KSP kinesin inhibitory activity (some data given).


IT 1092830-87-9P 1092830-97-1P 1092831-10-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of benzimidazole derivs. and related compds. as KSP inhibitors useful in treatment of KSP-associated diseases)

RN 1092830-87-9 CAPLUS



CN 1H-Benzimidazole-5-carboxamide, 2-[[4-(methylsulfonyl)phenyl]amino]-1-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 1092830-97-1 CAPLUS  
 CN 1H-Benzimidazole-5-carboxamide, 2-[[4-(aminosulfonyl)phenyl]amino]-1-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 1092831-10-1 CAPLUS  
 CN 1H-Benzimidazole-5-carboxamide, 2-[(4-methoxyphenyl)amino]-1-[[3-(trifluoromethyl)-2-pyridinyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:159875 CAPLUS

DOCUMENT NUMBER: 148:299037

TITLE: Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)

AUTHOR(S): Bonfanti, Jean-Francois; Meyer, Christophe; Doublet, Frederic; Fortin, Jerome; Muller, Philippe; Queguiner, Laurence; Gevers, Tom; Janssens, Peggy; Szel, Heidi;

Willebrords, Rudy; Timmerman, Philip; Wuyts, Koen; van Remoortere, Pieter; Janssens, Frans; Wigerinck, Piet; Andries, Koen

CORPORATE SOURCE: Medicinal Chemistry Department, Johnson and Johnson Pharmaceutical Research and Development, Val de Reuil, F-27106, Fr.

SOURCE: Journal of Medicinal Chemistry (2008), 51(4), 875-896  
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 148:299037

AB A preceding paper reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications that were necessary to achieve this goal also led to a significant drop in anti-RSV activity. This paper describes a mol. modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clin. candidate.

IT 857066-90-1P, 2-[[6-[[[2-(3-Hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of substituted benzimidazole derivs. as respiratory syncytial virus fusion inhibitors)

RN 857066-90-1 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



IT 857035-10-0P, 2-[[6-[(3,5-Dimethylphenylamino)methyl]-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857035-11-1P, 3-[[6-[(3,5-Dimethylphenylamino)methyl]-1-[(3-hydroxy-6-methylpyridin-2-yl)methyl]-1H-benzimidazol-2-yl]amino]propane-1,2-diol 857035-20-2P, 2-[[2-[[2-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl]amino]-6-[(3,5-dimethylphenylamino)methyl]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857035-23-5P, 2-[[6-[(3,5-Dimethylphenylamino)methyl]-2-phenethylaminobenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857066-95-6P, 2-[[6-[[[2-(3-Hydroxypropyl)phenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-08-4P, 2-[[6-[[[2-(2-Hydroxyethyl)phenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-09-5P, 2-[[6-[(3,5-Dimethylphenylamino)methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-14-2P, 6-Methyl-2-[[2-[[3-(morpholin-4-yl)propyl]amino]-6-[(m-tolylamino)methyl]benzimidazol-1-yl]methyl]pyridin-




3-ol 857067-44-8P, 2-[[6-[[[(3,5-Dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-45-9P  
 857067-72-2P, 2-[[6-[[[(2-Hydroxyethyl)-m-tolylamino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-83-5P, 2-[[6-[[[(2-Hydroxyethyl)(phenyl)amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 1009646-66-5P, 2-[[2-[Butylamino]-6-[(3,5-dimethylphenylamino)methyl]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted benzimidazole derivs. as respiratory syncytial virus fusion inhibitors)


RN 857035-10-0 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-11-1 CAPLUS

CN 1,2-Propanediol, 3-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 857035-20-2 CAPLUS


CN 3-Pyridinol, 2-[[2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-6-[[[(3,5-dimethylphenyl)amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-23-5 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[(2-phenylethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857066-95-6 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxypropyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-08-4 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-09-5 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-14-2 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[6-[[[(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857067-44-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-45-9 CAPLUS


CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-72-2 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-83-5 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)phenylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 1009646-66-5 CAPLUS  
 CN 3-Pyridinol, 2-[[2-(butylamino)-6-[[[(3,5-dimethylphenyl)amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 857035-14-4P, 2-[[6-Hydroxymethyl-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol  
 857035-19-9P, 2-[[5-Hydroxymethyl-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol  
 857035-24-6P, 2-[[6-Hydroxymethyl-2-phenethylaminobenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-38-0P,  
 2-[[6-Hydroxymethyl-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-39-1P,  
 2-[[5-Hydroxymethyl-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857070-63-4P,  
 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]-3H-benzimidazole-5-carboxylic acid Ethyl Ester  
 857070-64-5P, 1-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]-1H-benzimidazole-5-carboxylic acid Ethyl Ester 857070-65-6P, 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]-3H-benzimidazole-5-carboxaldehyde  
 857070-68-9P 1009646-51-8P,  
 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]-3H-benzimidazole-5-carboxylic acid Ethyl Ester  
 1009646-52-9P, 1-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]-1H-benzimidazole-5-carboxylic acid Ethyl Ester 1009646-53-0P,  
 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]-3H-benzimidazole-5-carboxaldehyde 1009646-56-3P  
 , 2-[[2-[[2,2-Dimethyl-[1,3]dioxolan-4-yl]methyl]amino]-3-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-3H-benzimidazole-5-carboxylic acid Ethyl Ester  
 1009646-57-4P, 2-[[2-[[2,2-Dimethyl-[1,3]dioxolan-4-yl]methyl]amino]-1-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-1H-benzimidazole-5-carboxylic acid Ethyl Ester 1009646-58-5P,  
 2-[[2-[[2,2-Dimethyl-[1,3]dioxolan-4-yl]methyl]amino]-6-hydroxymethylbenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol  
 1009646-59-6P, 2-[[2-[[2,2-Dimethyl-[1,3]dioxolan-4-yl]methyl]amino]-5-hydroxymethylbenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 1009646-60-9P, 2-[[2-[[2,2-Dimethyl-[1,3]dioxolan-4-yl]methyl]amino]-3-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-3H-benzimidazole-5-carboxaldehyde 1009646-62-1P,  
 2-Butylamino-3-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-3H-benzimidazole-5-carboxylic Acid Ethyl Ester 1009646-63-2P,  
 2-Butylamino-1-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-1H-benzimidazole-5-carboxylic Acid Ethyl Ester 1009646-64-3P,  
 2-[[2-[[Butylamino]-6-hydroxymethylbenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 1009646-65-4P,  
 2-Butylamino-3-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-3H-benzimidazole-5-carboxaldehyde 1009646-68-7P,  
 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-phenethylamino-3H-benzimidazole-5-carboxylic Acid Ethyl Ester 1009646-69-8P,  
 1-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-phenethylamino-1H-benzimidazole-5-carboxylic acid Ethyl Ester 1009646-70-1P,  
 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-phenethylamino-3H-benzimidazole-5-carboxaldehyde  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of substituted benzimidazole derivs. as respiratory syncytial virus fusion inhibitors)


RN 857035-14-4 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (CA INDEX NAME)




RN 857035-19-9 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (CA INDEX NAME)




RN 857035-24-6 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]- (CA INDEX NAME)




RN 857067-38-0 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857067-39-1 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-63-4 CAPLUS

CN 1H-Benzimidazole-6-carboxylic acid, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)




RN 857070-64-5 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)



RN 857070-65-6 CAPLUS  
 CN 1H-Benzimidazole-6-carboxaldehyde,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-  
 morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-68-9 CAPLUS  
 CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-  
 benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 1009646-51-8 CAPLUS  
 CN 1H-Benzimidazole-6-carboxylic acid,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-  
 piperazinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1009646-52-9 CAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-  
 piperazinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)







RN 1009646-53-0 CAPLUS  
 CN 1H-Benzimidazole-6-carboxaldehyde,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-  
 piperazinyl)propyl]amino]- (CA INDEX NAME)




RN 1009646-56-3 CAPLUS  
 CN 1H-Benzimidazole-6-carboxylic acid,  
 2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1-[(3-hydroxy-6-methyl-2-  
 pyridinyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 1009646-57-4 CAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid,  
 2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1-[(3-hydroxy-6-methyl-2-  
 pyridinyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 1009646-58-5 CAPLUS  
 CN 1H-Benzimidazole-6-methanol, 2-[[ (2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 1009646-59-6 CAPLUS  
 CN 1H-Benzimidazole-5-methanol, 2-[[ (2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 1009646-60-9 CAPLUS  
 CN 1H-Benzimidazole-6-carboxaldehyde, 2-[[ (2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 1009646-62-1 CAPLUS  
 CN 1H-Benzimidazole-6-carboxylic acid,  
 2-(butylamino)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, ethyl ester  
 (CA INDEX NAME)



RN 1009646-63-2 CAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid,  
 2-(butylamino)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, ethyl ester  
 (CA INDEX NAME)




RN 1009646-64-3 CAPLUS  
 CN 1H-Benzimidazole-6-methanol, 2-(butylamino)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 1009646-65-4 CAPLUS  
 CN 1H-Benzimidazole-6-carboxaldehyde,  
 2-(butylamino)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)


NAME)




RN 1009646-68-7 CAPLUS  
CN 1H-Benzimidazole-6-carboxylic acid,  
1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]-,  
ethyl ester (CA INDEX NAME)



RN 1009646-69-8 CAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid,  
1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]-,  
ethyl ester (CA INDEX NAME)



RN 1009646-70-1 CAPLUS  
CN 1H-Benzimidazole-6-carboxaldehyde,  
1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]- (CA  
INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2007:954101 CAPLUS

DOCUMENT NUMBER: 147:377573  
 TITLE: Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. Improving the Pharmacokinetic Profile Using the Structure-Property Relationship  
 AUTHOR(S): Bonfanti, Jean-Francois; Doublet, Frederic; Fortin, Jerome; Lacrampe, Jean; Guillemont, Jerome; Muller, Philippe; Queguiner, Laurence; Arnoult, Eric; Gevers, Tom; Janssens, Peggy; Szel, Heidi; Willebrords, Rudy; Timmerman, Philip; Wuyts, Koen; Janssens, Frans; Sommen, Cois; Wigerinck, Piet; Andries, Koen  
 CORPORATE SOURCE: Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research and Development, Val de Reuil, F-27106, Fr.  
 SOURCE: Journal of Medicinal Chemistry (2007), 50(19), 4572-4584  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 147:377573


AB The authors previously reported the discovery of substituted benzimidazole fusion inhibitors with nanomolar activity against respiratory syncytial virus. A lead compound of the series was selected for preclin. evaluation. This drug candidate, JNJ-2408068 (formerly R170591, 1), showed long tissue retention times in several species (rat, dog, and monkey), creating cause for concern. The authors herein describe the optimization program to develop compds. with improved properties in terms of tissue retention. The authors have identified the aminoethyl-piperidine moiety as being responsible for the long tissue retention time of 1. The authors have investigated the replacement or the modification of this group, and suggest that the pKa of this part of the mols. influences both the antiviral activity and the pharmacokinetic profile. The authors were able to identify new respiratory syncytial virus inhibitors with shorter half-lives in lung tissue.

IT 856894-98-9P 856894-99-0P 857068-40-7P  
 950483-51-9P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (selection of a respiratory syncytial virus fusion inhibitor clin. candidate through improving the pharmacokinetic profile using the structure-property relationship)

RN 856894-98-9 CAPLUS


CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 856894-99-0 CAPLUS


CN 1,2-Propanediol, 3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-

dimethyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 857068-40-7 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 950483-51-9 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(methylamino)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 950483-30-4

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(selection of a respiratory syncytial virus fusion inhibitor clin. candidate through improving the pharmacokinetic profile using the structure-property relationship)

RN 950483-30-4 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-(aminopropyl)amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 856895-02-8P 856895-13-1P 950483-53-1P  
950483-55-3P 950483-57-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(selection of a respiratory syncytial virus fusion inhibitor clin. candidate through improving the pharmacokinetic profile using the structure-property relationship)


RN 856895-02-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[(3-hydroxypropyl)amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-13-1 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[(2-phenylethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 950483-53-1 CAPLUS


CN Acetamide, N-[[2-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]ethyl]- (CA INDEX NAME)



RN 950483-55-3 CAPLUS  
 CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[2-(phenylamino)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 950483-57-5 CAPLUS  
 CN 3-Pyridinol, 2-[[2-(butylamino)-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 856895-07-3P 856895-15-3P 856895-41-5P  
 950483-42-8P 950483-44-0P 950483-46-2P  
 950483-48-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (selection of a respiratory syncytial virus fusion inhibitor clin. candidate through improving the pharmacokinetic profile using the structure-property relationship)  
 RN 856895-07-3 CAPLUS  
 CN  $\beta$ -Alanine, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]-, ethyl ester (CA INDEX NAME)






RN 856895-15-3 CAPLUS

CN 3-Pyridinol, 2-[[2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-41-5 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]- (CA INDEX NAME)




RN 950483-42-8 CAPLUS

CN 1H-Benzimidazol-2-amine, 4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 950483-44-0 CAPLUS

CN 1,3-Propanediamine, N1-[4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]-N3-methyl- (CA INDEX NAME)




RN 950483-46-2 CAPLUS

CN Acetamide, N-[2-[4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]amino]ethyl- (CA INDEX NAME)



RN 950483-48-4 CAPLUS

CN 1,2-Ethanediamine, N1-[4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]-N2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:1356990 CAPLUS  
 DOCUMENT NUMBER: 146:100696  
 TITLE: Preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus (RSV)  
 INVENTOR(S): Bonfanti, Jean-Francois; Muller, Philippe; Fortin, Jerome Michel Claude; Doublet, Frederic Marc Maurice  
 PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd, Ire.  
 SOURCE: PCT Int. Appl., 52pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006136561	A1	20061228	WO 2006-EP63365	20060620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006260969	A1	20061228	AU 2006-260969	20060620
CA 2612263	A1	20061228	CA 2006-2612263	20060620
EP 1896473	A1	20080312	EP 2006-763808	20060620
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008546738	T	20081225	JP 2008-517487	20060620
IN 2007DN09456	A	20080620	IN 2007-DN9456	20071207
MX 200716537	A	20080306	MX 2007-16537	20071218
CN 101203517	A	20080618	CN 2006-80021972	20071219
PRIORITY APPLN. INFO.:			EP 2005-76438	A 20050620
			WO 2006-EP63365	W 20060620
OTHER SOURCE(S):	CASREACT 146:100696; MARPAT 146:100696			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I [R = II or III; Q = H or alkyl optionally substituted with a heterocycle or Q = alkyl substituted with both a radical -OR4 and a heterocycle; Alk = alkanediyl; X = O or S; a1:a2a3:a4 = N:CHCH:CH, CH:NCH:CH, CH:CHN:CH or CH:CHCH:N; R1 = Ar or a heterocycle; R2 = H, (un)substituted alkyl, cycloalkyl; R3 = H, alkyl, cyano, aminocarbonyl, polyhaloalkyl, alkenyl or alkynyl; R4 = H or alkyl; Ar = (un)substituted Ph; and their salts], useful as inhibitors of RSV replication, were prepared E.g., a multi-step synthesis of IV, starting from V, was given.  
 Exemplified compds. I were screened in vitro for their activity against respiratory syncytial virus (pEC50 values were provided). Pharmaceutical compns. containing compds. I and processes for preparing compds. I were

disclosed.


IT 918151-94-7P 918151-95-8P 918151-96-9P  
918151-97-0P 918151-98-1P 918152-00-8P  
918152-01-9P 918152-03-1P 918152-04-2P  
918152-05-3P 918152-06-4P 918152-07-5P  
918152-08-6P 918152-10-0P 918152-11-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus)

RN 918151-94-7 CAPLUS


CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)





RN 918151-97-0 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-[2-(phenylmethoxy)ethyl]-, inner salt (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


—CH<sub>2</sub>—Ph

RN 918151-98-1 CAPLUS  
 CN 1H-Benzimidazole-5-carbonitrile, 1-cyclopropyl-2,3-dihydro-3-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo- (CA INDEX NAME)




RN 918152-00-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-(3-phenylpropyl)-, inner salt (CA INDEX NAME)



RN 918152-01-9 CAPLUS


CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-(2-phenylethyl)-, inner salt, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 918152-03-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1-cyclopropyl-1,3-dihydro-3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]- (CA INDEX NAME)




RN 918152-04-2 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3-(2-phenylethyl)- (CA INDEX NAME)




RN 918152-05-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)




RN 918152-06-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)




RN 918152-07-5 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-(2-phenylethyl)-, inner salt (CA INDEX NAME)




RN 918152-08-6 CAPLUS  
 CN 1H-Imidazo[4,5-c]pyridinium, 1-[2-(4-fluorophenyl)ethyl]-2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)

PAGE 1-A









RN 918152-10-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)



RN 918152-11-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3-(3-phenylpropyl)- (CA INDEX NAME)




IT 857067-38-0 857071-29-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus)



RN 857067-38-0 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857071-29-5 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



IT 857070-36-1P 857070-68-9P 857071-34-2P

918152-25-7P 918152-26-8P 918152-27-9P



918152-28-0P 918152-30-4P 918152-31-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus)


RN 857070-36-1 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-68-9 CAPLUS

CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 857071-34-2 CAPLUS  
 CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl


RN 918152-25-7 CAPLUS  
 CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)



RN 918152-26-8 CAPLUS  
 CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)




RN 918152-27-9 CAPLUS  
 CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 918152-28-0 CAPLUS  
 CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)





RN 918152-30-4 CAPLUS  
 CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 918152-31-5 CAPLUS  
 CN 3-Pyridinol, 2-[[5-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl

IT 1062064-57-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus)  
 RN 1062064-57-6 CAPLUS  
 CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1356649 CAPLUS

DOCUMENT NUMBER: 146:100692

TITLE: Preparation of 2-substituted benzimidazoles as respiratory syncytial virus (RSV) replication inhibitors

INVENTOR(S): Bonfanti, Jean-Francois; Muller, Philippe; Fortin, Jerome Michel Claude; Doublet, Frederic Marc Maurice

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd, Ire.

SOURCE: PCT Int. Appl., 42pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006136563	A1	20061228	WO 2006-EP63367	20060620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006260971	A1	20061228	AU 2006-260971	20060620
CA 2612265	A1	20061228	CA 2006-2612265	20060620
EP 1896450	A1	20080312	EP 2006-777372	20060620
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008546740	T	20081225	JP 2008-517489	20060620
IN 2007DN09650	A	20080620	IN 2007-DN9650	20071213
MX 200716313	A	20080307	MX 2007-16313	20071217
CN 101203507	A	20080618	CN 2006-80022016	20071219
PRIORITY APPLN. INFO.:			EP 2005-76440	A 20050620
			WO 2006-EP63367	W 20060620

OTHER SOURCE(S): MARPAT 146:100692

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I [Q = H, alkyl optionally substituted with a heterocycle or Q = alkyl substituted with both OR4 and a heterocycle (wherein said heterocycle = oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, etc.); each Alk = alkanediyl; R1 = Ar2 or (un)substituted piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridyl, etc.; R2 = H or alkyl; R3, R4 = H, alkyl, hydroxyalkyl, etc.; Ar2 = (un)substituted Ph], useful as inhibitors of RSV replication, were prepared E.g., a multi-step synthesis of II, starting with III and IV, was given. Exemplified compds. I were screened in vitro for activity against respiratory syncytial virus (pEC50 values were given). Pharmaceutical

composition comprising the compound I is disclosed.


IT 918155-50-7P 918155-62-1P 918155-63-2P  
918155-64-3P 918155-65-4P 918155-66-5P  
918155-67-6P 918155-68-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of 2-substituted benzimidazoles as respiratory syncytial virus  
(RSV) replication inhibitors)


RN 918155-50-7 CAPLUS

CN Acetamide, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-6-[[[2-(3-  
hydroxypropyl)-5-methylphenyl]amino]methyl]-1H-benzimidazol-2-yl]- (CA  
INDEX NAME)




RN 918155-62-1 CAPLUS

CN Acetamide, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-6-[[[2-(3-  
hydroxypropyl)phenyl]amino]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-63-2 CAPLUS

CN Acetamide, N-[6-[[[(3,5-dichlorophenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-  
2-pyridinyl)methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-64-3 CAPLUS

CN Acetamide, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-6-[[[(3-  
methylphenyl)amino]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-65-4 CAPLUS

CN Acetamide, N-[6-[[[(3-ethynylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]]- (CA INDEX NAME)




RN 918155-66-5 CAPLUS

CN Acetamide, N-[6-[[[(2,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]]- (CA INDEX NAME)



RN 918155-67-6 CAPLUS


CN Acetamide, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-6-[[[2-[2-(4-morpholinyl)ethyl]phenyl]amino]methyl]-1H-benzimidazol-2-yl]]- (CA INDEX NAME)



RN 918155-68-7 CAPLUS



CN Benzenepropanamide, 2-[[[2-(acetylamino)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




IT 918155-70-1P 918155-71-2P 918155-72-3P  
918155-73-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-substituted benzimidazoles as respiratory syncytial virus (RSV) replication inhibitors)


RN 918155-70-1 CAPLUS

CN Acetamide, N-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-71-2 CAPLUS

CN Acetamide, N-[6-(hydroxymethyl)-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-72-3 CAPLUS

CN Acetamide, N-[6-formyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 918155-73-4 CAPLUS

CN Acetamide, N-[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1355985 CAPLUS

DOCUMENT NUMBER: 146:100688

TITLE: Preparation of heterocycllaminoalkyl substituted benzimidazoles as respiratory syncytial virus (RSV) replication inhibitors

INVENTOR(S): Bonfanti, Jean-Francois; Muller, Philippe; Fortin, Jerome Michel Claude; Doublet, Frederic Marc Maurice

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd, Ire.

SOURCE: PCT Int. Appl., 40pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006136562	A1	20061228	WO 2006-EP63366	20060620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006260970	A1	20061228	AU 2006-260970	20060620






RN 918153-22-7 CAPLUS

CN 2-Pyridineethanol, 3-[[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 918153-23-8 CAPLUS

CN 4-Pyridineethanol, 3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 918153-24-9 CAPLUS

CN 4-Pyridineethanol, 3-[[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 918153-25-0 CAPLUS

CN 2-Pyridineethanol, 3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-5-methyl-  
(CA INDEX NAME)



RN 918153-27-2 CAPLUS

CN 2-Pyridineethanol, 3-[[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-5-methyl-  
(CA INDEX NAME)



IT 857067-38-0P 857067-39-1P 857070-36-1P


857070-65-6P 857071-29-5P 857071-32-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of heterocyclaminoalkyl substituted benzimidazoles as  
respiratory syncytial virus (RSV) replication inhibitors)


RN 857067-38-0 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-  
[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857067-39-1 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-36-1 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-65-6 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857071-29-5 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857071-32-0 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:570884 CAPLUS

DOCUMENT NUMBER: 143:97367



TITLE: Preparation of 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication

INVENTOR(S): Bonfanti, Jean-francois; Andries, Koenraad Jozef Lodewijk; Fortin, Jerome Michel Claude; Muller,

PATENT ASSIGNEE(S): Philippe; Doublet, Frederic Marc Maurice; Meyer,  
 SOURCE: Christophe; Willebrords, Rudy Edmond; Gevers, Tom  
 Valerius Josepha; Timmerman, Philip Maria Martha Bern  
 Tibotec Pharmaceuticals Ltd., Ire.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058874	A1	20050630	WO 2004-EP53618	20041220
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004298459	A1	20050630	AU 2004-298459	20041220
CA 2548793	A1	20050630	CA 2004-2548793	20041220
EP 1697347	A1	20060906	EP 2004-804954	20041220
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
CN 1914196	A	20070214	CN 2004-80041654	20041220
BR 2004017273	A	20070327	BR 2004-17273	20041220
JP 2007514719	T	20070607	JP 2006-544465	20041220
IN 2006DN03418	A	20070420	IN 2006-DN3418	20060614
US 20070093502	A1	20070426	US 2006-596521	20060615
MX 2006007111	A	20060823	MX 2006-7111	20060619
KR 2006127047	A	20061211	KR 2006-714248	20060714
PRIORITY APPLN. INFO.:			EP 2003-104806	A 20031218
			US 2004-566867P	P 20040430
			WO 2004-EP53618	W 20041220
OTHER SOURCE(S):	CASREACT 143:97367; MARPAT 143:97367			
GI				





AB The title compds. I [Q = Ar2, R6, pyrrolidinyl substituted with R6, piperidinyl substituted with R6 or homopiperidinyl substituted with R6; G = a direct bond or (un)substituted alkanediyl; R1 = Ar1 or a monocyclic or bicyclic heterocycle; one of R2a and R2b = cyanoalkyl, cyanoalkenyl, Ar3(alkyl), Het(alkyl), etc., and the other one of R2a and R2b = H; in case R2a = H, then R3 = H; in case R2b = H, the R3 = H or alkyl; R5 = H, alkyl; R6 = H, (un)substituted alkyl, etc.; Ar1, Ar2 = (un)substituted Ph; Ar3 = (un)substituted Ph, naphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, indanyl; heterocycle; and a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochem. isomeric form thereof] having inhibitory activity on the replication of the respiratory syncytial virus, were prepared E.g., a multi-step synthesis of II, starting from Et 3,4-diaminobenzoate, was given. The exemplified compds. I were tested for activity against RSV (data given). The pharmaceutical composition comprising the compound I is disclosed.


IT 857035-13-3P 857035-18-8P 857035-20-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 5- or 6-substituted benzimidazole derivs. as inhibitors of respiratory syncytial virus replication)


RN 857035-13-3 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(1-piperidinyl)propyl]amino]- (CA INDEX NAME)




RN 857035-18-8 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-  
[[3-(1-piperidinyl)propyl]amino]- (CA INDEX NAME)



RN 857035-20-2 CAPLUS

CN 3-Pyridinol, 2-[[2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-6-  
[[3,5-dimethylphenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




IT 857035-09-7P 857035-10-0P 857035-11-1P  
857035-12-2P 857035-14-4P 857035-15-5P  
857035-16-6P 857035-17-7P 857035-19-9P  
857035-21-3P 857035-22-4P 857035-23-5P  
857035-24-6P 857035-25-7P 857035-26-8P  
857035-27-9P 857035-28-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of 5- or 6-substituted benzimidazole derivs. as inhibitors of  
respiratory syncytial virus replication)

RN 857035-09-7 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(1-  
piperidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA  
INDEX NAME)



RN 857035-10-0 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-methyl-1-  
piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA

INDEX NAME)




RN 857035-11-1 CAPLUS

CN 1,2-Propanediol, 3-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 857035-12-2 CAPLUS

CN 3-Pyridinol, 2-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(1-piperidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-14-4 CAPLUS


CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (CA INDEX NAME)




RN 857035-15-5 CAPLUS  
 CN 3-Pyridinol, 2-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-16-6 CAPLUS  
 CN 1,2-Propanediol, 3-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)



RN 857035-17-7 CAPLUS  
 CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-methoxyphenyl)ethyl]amino]- (CA INDEX NAME)




RN 857035-19-9 CAPLUS  
 CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (CA INDEX NAME)




RN 857035-21-3 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]- (CA INDEX NAME)




RN 857035-22-4 CAPLUS

CN 3-Pyridinol, 2-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-2-[(2-phenylethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-23-5 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[(2-phenylethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-24-6 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]- (CA INDEX NAME)




RN 857035-25-7 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-methoxyphenyl)ethyl]amino]- (CA INDEX NAME)




RN 857035-26-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[2-(4-methoxyphenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




RN 857035-27-9 CAPLUS

CN 3-Pyridinol, 2-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[2-(4-methoxyphenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




RN 857035-28-0 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[(3,5-dichlorophenyl)amino]methyl]-2-[[2-(4-methoxyphenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




IT 857035-58-6P 857035-59-7P 857035-60-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 5- or 6-substituted benzimidazole derivs. as inhibitors of  
 respiratory syncytial virus replication)  
 RN 857035-58-6 CAPLUS  
 CN 1H-Benzimidazole-6-carboxylic acid,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(1-  
 piperidinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)



RN 857035-59-7 CAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(1-  
 piperidinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)



RN 857035-60-0 CAPLUS  
 CN 1H-Benzimidazole-6-carboxaldehyde,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(1-  
 piperidinyl)propyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:570883 CAPLUS

DOCUMENT NUMBER: 143:97366

TITLE: Preparation of aminobenzimidazoles as inhibitors of respiratory syncytial virus replication

INVENTOR(S): Bonfanti, Jean-francois; Andries, Koenraad Jozef Lodewijk; Fortin, Jerome Michel Claude; Muller, Philippe; Doublet, Frederic Marc Maurice; Meyer, Christophe; Willebrords, Rudy Edmond; Gevers, Tom Valerius Josepha; Timmerman, Philip Maria Martha Bern

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058869	A1	20050630	WO 2004-EP53613	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004298457	A1	20050630	AU 2004-298457	20041220
CA 2548657	A1	20050630	CA 2004-2548657	20041220
EP 1697343	A1	20060906	EP 2004-804949	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1918146	A	20070221	CN 2004-80041689	20041220
BR 2004017811	A	20070327	BR 2004-17811	20041220
JP 2007514717	T	20070607	JP 2006-544463	20041220
IN 2006DN03296	A	20070420	IN 2006-DN3296	20060608
US 20070099924	A1	20070503	US 2006-596514	20060615
MX 2006007108	A	20060818	MX 2006-7108	20060619
NO 2006003218	A	20060711	NO 2006-3218	20060711
KR 2006127879	A	20061213	KR 2006-714232	20060714
PRIORITY APPLN. INFO.:			EP 2003-104797	A 20031218



US 2004-566834P


P 20040430

WO 2004-EP53613


W 20041220

OTHER SOURCE(S):  
GI

CASREACT 143:97366; MARPAT 143:97366



I



II

AB The title compds. I [G = a direct bond or (un)substituted alkanediyl; R1 = Ar1 or a monocyclic or bicyclic heterocycle; Q = H, amino or mono- or dialkylamino; one of R2a and R3a = halo, optionally mono- or polysubstituted alkyl, optionally mono- or polysubstituted alkenyl, nitro, hydroxy, etc.; and the other one of R2a and R3a = H; in case R2a is different from hydrogen then R2b = H, alkyl or halogen and R3b = H; in case R3a is different from hydrogen then R3b = H, alkyl or halogen and R2b = H; R5 is not defined; Ar1 = (un)substituted Ph; and the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochem. isomeric forms thereof] having inhibitory activity on RSV replication, were prepared E.g., a multi-step synthesis of II, starting from Et 2-aminobenzimidazole-5-carboxylate, was given. The exemplified compds. I were tested for activity against RSV (data given). The pharmaceutical composition comprising the compound I is disclosed.

IT 856835-30-8P 856835-51-3P 856835-58-0P


856835-64-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminobenzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 856835-30-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(3-methylphenyl)amino]methyl]-2-(methylamino)-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856835-51-3 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-(methylamino)- (CA INDEX NAME)




RN 856835-58-0 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-(methylamino)- (CA INDEX NAME)



RN 856835-64-8 CAPLUS

CN 3-Pyridinol, 2-[[5-[[[(2-hydroxyethyl)(3-methylphenyl)amino]methyl]-2-(methylamino)-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 1060720-96-8P 1060721-93-8P 1060729-12-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminobenzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 1060720-96-8 CAPLUS

CN 1H-Benzimidazole-6-carboxylic acid, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(methoxycarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1060721-93-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid,  
1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(methoxycarbonyl)amino]-,  
ethyl ester (CA INDEX NAME)



RN 1060729-12-5 CAPLUS  
CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-(methylamino)-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:564655 CAPLUS

DOCUMENT NUMBER: 143:97374

TITLE: Preparation of morpholine containing benzimidazoles as inhibitors of respiratory syncytial virus replication

INVENTOR(S): Bonfanti, Jean-Francois; Andries, Koenraad Jozef Lodewijk; Fortin, Jerome Michel Claude; Muller, Philippe; Doublet, Frederic Marc Maurice; Meyer, Christophe; Willebrords, Rudy Edmond; Gevers, Tom Valerius Josepha; Timmerman, Philip Maria Martha Bern Tibotec Pharmaceuticals Ltd., Ire.

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058871	A1	20050630	WO 2004-EP53620	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
 MR, NE, SN, TD, TG

AU 2004298460	A1	20050630	AU 2004-298460	20041220
CA 2548668	A1	20050630	CA 2004-2548668	20041220
EP 1697345	A1	20060906	EP 2004-817576	20041220
EP 1697345	B1	20080312		



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,  
 HR, IS, YU, BA

CN 1894237	A	20070110	CN 2004-80037825	20041220
BR 2004017268	A	20070313	BR 2004-17268	20041220
JP 2007514720	T	20070607	JP 2006-544467	20041220
AT 388950	T	20080315	AT 2004-817576	20041220
ES 2303653	T3	20080816	ES 2004-817576	20041220
US 20070043022	A1	20070222	US 2006-563691	20060104
US 7449463	B2	20081111		
IN 2006DN03140	A	20070824	IN 2006-DN3140	20060601
MX 2006007112	A	20060823	MX 2006-7112	20060619
KR 2007015507	A	20070205	KR 2006-714047	20060712
NO 2006003322	A	20060918	NO 2006-3322	20060718
US 20080280881	A1	20081113	US 2008-140686	20080617

PRIORITY APPLN. INFO.:

EP 2003-104810	A	20031218
US 2004-567182P	P	20040430
EP 2004-105312	A	20041026
WO 2004-EP53620	W	20041220
US 2006-563691	A1	20060104

OTHER SOURCE(S): CASREACT 143:97374; MARPAT 143:97374  
 GI



AB The title compds. I [G = a direct bond or (un)substituted alkanediyl; R<sup>1</sup> = Ar<sup>1</sup> or a monocyclic or bicyclic heterocycle; Q = R<sup>7</sup>, pyrrolidinyl

substituted with R7, piperidinyl substituted with R7 or homopiperidinyl substituted with R7; one of R2a and R3a = halo, optionally mono- or polysubstituted alkyl, optionally mono- or polysubstituted alkenyl, nitro, hydroxy, etc.; and the other one of R2a and R3a = H; in case R2a is different from H atom then R2b = H, alkyl or halogen and R3b = H; in case R3a is different from H atom then R3b = H, alkyl or halogen and R2b = H; R5 = H, alkyl; Ar1 = (un)substituted Ph; R7 = alkyl substituted with heterocycle or alkyl substituted with both a radical OR8 and a heterocycle; R8 = H, alkyl, Arylalkyl; or a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochem. isomeric form thereof] having inhibitory activity on the replication of the respiratory syncytial virus, were prepared E.g., a multi-step synthesis of II, starting from Et 3,4-diaminobenzoate, was given. The compds. I were tested for activity against RSV (data given). The pharmaceutical composition comprising the

compound

I is disclosed.


IT 857067-38-0P 857067-39-1P 857068-61-2P  
857069-72-8P 857070-23-6P 857070-36-1P  
857070-37-2P 857070-98-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of morpholine containing benzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 857067-38-0 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857067-39-1 CAPLUS


CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857068-61-2 CAPLUS



CN 1H-Benzimidazole-6-methanol, 2-[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 857069-72-8 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-23-6 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-36-1 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857070-37-2 CAPLUS


CN 1H-Benzimidazole-5-methanol, 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857070-98-5 CAPLUS

CN 1H-Benzimidazole-5-methanol, 2-[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 857066-88-7P 857066-89-8P 857066-90-1P  
 857066-91-2P 857066-92-3P 857066-93-4P  
 857066-94-5P 857066-95-6P 857066-96-7P  
 857066-97-8P 857066-98-9P 857066-99-0P  
 857067-00-6P 857067-01-7P 857067-02-8P  
 857067-03-9P 857067-04-0P 857067-05-1P

857067-06-2P 857067-07-3P 857067-08-4P  
857067-09-5P 857067-10-8P 857067-11-9P  
857067-12-0P 857067-13-1P 857067-14-2P  
857067-15-3P 857067-16-4P 857067-17-5P  
857067-18-6P 857067-19-7P 857067-20-0P  
857067-21-1P 857067-22-2P 857067-23-3P  
857067-24-4P 857067-25-5P 857067-26-6P  
857067-27-7P 857067-28-8P 857067-29-9P  
857067-30-2P 857067-31-3P 857067-32-4P  
857067-33-5P 857067-34-6P 857067-35-7P  
857067-36-8P 857067-37-9P 857067-40-4P  
857067-41-5P 857067-42-6P 857067-43-7P  
857067-44-8P 857067-45-9P 857067-46-0P  
857067-47-1P 857067-48-2P 857067-49-3P  
857067-50-6P 857067-51-7P 857067-52-8P  
857067-53-9P 857067-54-0P 857067-55-1P  
857067-56-2P 857067-57-3P 857067-58-4P  
857067-59-5P 857067-60-8P 857067-61-9P  
857067-62-0P 857067-63-1P 857067-64-2P  
857067-65-3P 857067-66-4P 857067-67-5P  
857067-68-6P 857067-69-7P 857067-70-0P  
857067-71-1P 857067-72-2P 857067-73-3P  
857067-74-4P 857067-75-5P 857067-76-6P  
857067-77-7P 857067-78-8P 857067-79-9P  
857067-80-2P 857067-81-3P 857067-82-4P  
857067-83-5P 857067-84-6P 857067-85-7P  
857067-86-8P 857067-87-9P 857067-88-0P  
857067-89-1P 857067-90-4P 857067-91-5P  
857067-92-6P 857067-93-7P 857067-94-8P  
857067-95-9P 857067-96-0P 857067-97-1P  
857067-98-2P 857067-99-3P 857068-00-9P  
857068-01-0P 857068-02-1P 857068-03-2P  
857068-04-3P 857068-05-4P 857068-06-5P  
857068-07-6P 857068-08-7P 857068-09-8P  
857068-10-1P 857068-11-2P 857068-12-3P  
857068-13-4P 857068-14-5P 857068-15-6P  
857068-16-7P 857068-17-8P 857068-18-9P  
857068-19-0P 857068-20-3P 857068-21-4P  
857068-22-5P 857068-23-6P 857068-24-7P  
857068-25-8P 857068-26-9P 857068-27-0P  
857068-28-1P 857068-29-2P 857068-30-5P  
857068-31-6P 857068-32-7P 857068-33-8P  
857068-34-9P 857068-35-0P 857068-36-1P  
857068-37-2P 857068-38-3P 857068-39-4P  
857068-40-7P 857068-41-8P 857068-42-9P  
857068-43-0P 857068-44-1P 857068-45-2P  
857068-46-3P 857068-57-6P 857068-58-7P  
857068-59-8P 857068-60-1P 857068-62-3P  
857068-63-4P 857068-64-5P 857068-65-6P  
857068-66-7P 857068-67-8P 857068-68-9P  
857068-70-3P 857068-71-4P 857068-72-5P  
857068-81-6P 857068-88-3P 857068-94-1P  
857068-97-4P 857068-98-5P 857069-06-8P  
857069-17-1P 857069-18-2P 857069-25-1P  
857069-26-2P 857069-29-5P 857069-37-5P  
857069-38-6P 857069-41-1P 857069-43-3P  
857069-44-4P 857069-47-7P 857069-48-8P  
857069-50-2P 857069-51-3P 857069-54-6P  
857069-55-7P 857069-56-8P 857069-57-9P  
857069-75-1P 857069-76-2P 857069-79-5P  
857069-80-8P 857069-81-9P 857069-83-1P  
857069-84-2P 857069-91-1P 857069-97-7P




857070-00-9P 857070-04-3P 857070-09-8P  
 857070-10-1P 857070-11-2P 857070-12-3P  
 857070-15-6P 857070-18-9P 857070-19-0P  
 857070-20-3P 857070-21-4P 857070-22-5P  
 857070-24-7P 857070-25-8P 857070-27-0P  
 857070-29-2P 857070-30-5P 857070-34-9P  
 857070-40-7P 857070-41-8P 857070-43-0P  
 857070-59-8P 857070-60-1P 857070-61-2P  
 857071-23-9P 857083-26-2P 857083-27-3P  
 857083-28-4P 857083-29-5P 857083-30-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of morpholine containing benzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 857066-88-7 CAPLUS

CN Benzonitrile, 4-(2-hydroxyethyl)-3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857066-89-8 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[5-bromo-2-(3-hydroxypropyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857066-90-1 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857066-91-2 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[5-chloro-2-(3-hydroxypropyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




RN 857066-92-3 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethoxy)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




RN 857066-93-4 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[5-ethenyl-2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




RN 857066-94-5 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 (CA INDEX NAME)




RN 857066-95-6 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxypropyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA  
 INDEX NAME)



RN 857066-96-7 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-methoxyphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
 (CA INDEX NAME)




RN 857066-97-8 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[5-bromo-2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA  
 INDEX NAME)




RN 857066-98-9 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-[(2-hydroxyethyl)sulfonyl]-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857066-99-0 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxypropyl)-5-(trifluoromethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-00-6 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxypropyl)-5-methoxyphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-01-7 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxybutyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-02-8 CAPLUS

CN Benzenepropanamide, 2-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-methyl- (CA INDEX NAME)




RN 857067-03-9 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-(1-methylethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-04-0 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[5-fluoro-2-(2-hydroxyethyl)phenyl]amino]methyl]-2-  
[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




RN 857067-05-1 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(3-hydroxy-1-propen-1-yl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-06-2 CAPLUS


CN 3-Pyridinol, 2-[[[6-[[[2-(4-hydroxybutyl)-5-methylphenyl]amino]methyl]-2-  
[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




RN 857067-07-3 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dichlorophenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-08-4 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-09-5 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-10-8 CAPLUS  
 CN Benzenepropanamide, 2-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 857067-11-9 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-3-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-12-0 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[3-(3-bromophenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-13-1 CAPLUS

CN Benzonitrile, 2-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)







RN 857067-14-2 CAPLUS  
 CN 3-Pyridinol, 6-methyl-2-[[6-[[3-(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)



RN 857067-15-3 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[2-(hydroxymethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-16-4 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[3-(ethynylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-17-5 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3-chlorophenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-18-6 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(hydroxymethyl)-4-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-19-7 CAPLUS

CN Benzenepropanamide, 2-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-20-0 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxy-1-propyn-1-yl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-21-1 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(3-fluorophenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-22-2 CAPLUS  
 CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(4-morpholinyl)propyl]amino]-6-[[[3-(trifluoromethoxy)phenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857067-23-3 CAPLUS  
 CN Benzenesulfonamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-24-4 CAPLUS  
 CN Benzamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-25-5 CAPLUS  
 CN 3-Pyridinol, 2-[[[6-[[[2-[(2-hydroxyethyl)amino]-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)



RN 857067-26-6 CAPLUS  
 CN 3-Pyridinol, 2-[[[6-[[[2-(2,5-dimethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




RN 857067-27-7 CAPLUS  
 CN 3-Pyridinol, 2-[[[6-[[[2-(2-ethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




RN 857067-28-8 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[6-[[[2-[2-(4-morpholinyl)ethyl]phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857067-29-9 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(hydroxymethyl)-3-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-30-2 CAPLUS

CN Benzamide, 4-(2-hydroxyethyl)-3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-31-3 CAPLUS

CN Benzanide, 2-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-32-4 CAPLUS

CN Benzenepropanenitrile, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-3-methyl- (CA INDEX NAME)




RN 857067-33-5 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[3-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-34-6 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-(methylsulfonyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-35-7 CAPLUS

CN Benzenepropanenitrile, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-3,5-dimethyl- (CA INDEX NAME)




RN 857067-36-8 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[2-iodo-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-37-9 CAPLUS  
 CN 3-Pyridinol, 2-[[5-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-40-4 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-(3-thienyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-41-5 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[5-(3-furanyl)-2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)






RN 857067-42-6 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-(2-thienyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




RN 857067-43-7 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[5-(2-furanyl)-2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




RN 857067-44-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




RN 857067-45-9 CAPLUS

CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-46-0 CAPLUS

CN Propanamide, 3-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-47-1 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(4-hydroxybutyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-48-2 CAPLUS

CN Butanoic acid, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-49-3 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(3-hydroxypropyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-50-6 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(5-hydroxypentyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-51-7 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)[2-(4-morpholinyl)ethyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-52-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2-aminoethyl)(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-53-9 CAPLUS


CN Phosphoric acid, 2-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]ethyl diethyl ester (CA INDEX NAME)




RN 857067-54-0 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)[3-(4-morpholinyl)propyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-55-1 CAPLUS  
 CN  $\beta$ -Alanine, N-(3,5-dimethylphenyl)-N-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]- (CA INDEX NAME)




RN 857067-56-2 CAPLUS  
 CN Phosphonic acid, [2-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 857067-57-3 CAPLUS

CN Butanoic acid, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-, ethyl ester (CA INDEX NAME)




RN 857067-58-4 CAPLUS

CN  $\beta$ -Alanine, N-(3,5-dimethylphenyl)-N-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-, ethyl ester (CA INDEX NAME)




RN 857067-59-5 CAPLUS

CN 1-Propanesulfonamide, 3-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-60-8 CAPLUS

CN 1-Butanesulfonamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-61-9 CAPLUS

CN Pentanamide, 5-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-62-0 CAPLUS

CN 1-Propanesulfonamide, 3-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-N-methyl- (CA INDEX NAME)




RN 857067-63-1 CAPLUS

CN Butanamide, 4-[[3,5-dimethylphenyl][[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-N-methyl- (CA INDEX NAME)



RN 857067-64-2 CAPLUS


CN 3-Pyridinol, 2-[[6-[[3,5-dimethylphenyl](2-hydroxy-3-methylbutyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-65-3 CAPLUS

CN 3-Pyridinol, 2-[[6-[[3,5-dimethylphenyl][2-(2-hydroxyethoxy)ethyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)







RN 857067-66-4 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(2-hydroxy-3-phenoxypropyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-67-5 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(1H-imidazol-5-ylmethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-68-6 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(2-methoxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-69-7 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[3,5-dimethylphenyl](2-hydroxy-3-phenylpropyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 857067-70-0 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[3,5-dimethylphenyl](2-hydroxy-3,3-dimethylbutyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-71-1 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[3-bromophenyl](2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-72-2 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-73-3 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]- (CA INDEX NAME)




RN 857067-74-4 CAPLUS

CN Benzonitrile, 4-[(2-hydroxyethyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-75-5 CAPLUS

CN Propanamide, 3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]- (CA INDEX NAME)




RN 857067-76-6 CAPLUS

CN Butanamide, 4-[(3-bromophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-77-7 CAPLUS

CN 1-Butanesulfonamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]- (CA INDEX NAME)




RN 857067-78-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[4-(4-hydroxybutyl)(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-79-9 CAPLUS

CN 3-Pyridinol, 2-[[6-[[3-(3-hydroxypropyl)(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-80-2 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[6-[[3-(3-methylphenyl)-2-(4-morpholinylethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857067-81-3 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[(3-bromophenyl)(3-hydroxypropyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-82-4 CAPLUS

CN Butanamide, 4-[[[(4-cyanophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-83-5 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[(2-hydroxyethyl)phenylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-84-6 CAPLUS

CN 1-Propanesulfonamide, 3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]-N-methyl- (CA INDEX NAME)




RN 857067-85-7 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(dimethylamino)ethyl](3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-86-8 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(dimethylamino)ethyl](3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-87-9 CAPLUS

CN Acetamide, 2-[[2-(2-hydroxyethyl)phenyl][[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857067-88-0 CAPLUS


CN Butanoic acid, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl] (3-methylphenyl)amino]-, methyl ester (CA INDEX NAME)



RN 857067-89-1 CAPLUS


CN 3-Pyridinol, 2-[[[6-[[[2-(2-hydroxyethyl)phenyl][2-(4-morpholinyl)ethyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)






RN 857067-90-4 CAPLUS

CN Propanamide, 3-[[[3-(2-hydroxyethyl)phenyl][[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-91-5 CAPLUS

CN Benzamide, 4-[[[3-(2-hydroxyethyl)phenyl][[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-92-6 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[4-(hydroxyphenyl)phenylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




RN 857067-93-7 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-94-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(aminomethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-95-9 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3-hydroxyphenyl)phenylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-96-0 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(2-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-97-1 CAPLUS

CN Benzamide, 2-[(2-hydroxyethyl) [[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-98-2 CAPLUS

CN 1-Propanesulfonamide, 3-[(3-ethynylphenyl) [[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-99-3 CAPLUS

CN Propanamide, 3-[(3-bromophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-00-9 CAPLUS

CN Butanamide, 4-[(3-ethynylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-01-0 CAPLUS

CN Propanamide, 3-[(3-ethynylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-02-1 CAPLUS

CN Butanoic acid, 4-[(3-ethynylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-03-2 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3-bromophenyl)(4-hydroxybutyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




RN 857068-04-3 CAPLUS

CN Propanamide, 3-[(4-cyanophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-05-4 CAPLUS

CN Benzonitrile, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-hydroxypropyl)amino]- (CA INDEX NAME)




RN 857068-06-5 CAPLUS

CN Benzenesulfonamide, 4-[(2-hydroxyethyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-07-6 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[(3-fluorophenyl)(2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-08-7 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)phenyl]methylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-09-8 CAPLUS

CN Butanamide, 4-[(3,5-dichlorophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-10-1 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dichlorophenyl)(4-hydroxybutyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-11-2 CAPLUS

CN Propanamide, 3-[[2,5-dimethylphenyl][[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857068-12-3 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl][2-methyl-5-(1-methylethyl)phenyl]amino]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 857068-13-4 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl][2,3,5-




trimethylphenyl)amino]- (CA INDEX NAME)




RN 857068-14-5 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2,5-dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857068-15-6 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)[2-methyl-5-(1-methylethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857068-16-7 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(2,3,5-trimethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-

(CA INDEX NAME)




RN 857068-17-8 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3-quinolinylamino]-  
(CA INDEX NAME)




RN 857068-18-9 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(2-hydroxyethyl)-3-quinolinylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol]-  
(CA INDEX NAME)




RN 857068-19-0 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-pyrimidinylamino]-  
(CA INDEX NAME)




RN 857068-20-3 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)-2-pyrimidinylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-21-4 CAPLUS

CN Butanamide, 4-[(1-ethyl-1H-pyrazol-5-yl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-22-5 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(1-ethyl-1H-pyrazol-5-yl)(2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-23-6 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-4-pyridinylamino]- (CA INDEX NAME)




RN 857068-24-7 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[(2-hydroxyethyl)(5-methyl-3-isoxazolyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-2-[[4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3,5-dimethylphenyl]amino]-, ethyl ester (CA INDEX NAME)




RN 857068-25-8 CAPLUS

CN Butanoic acid, 4-[[[4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3,5-dimethylphenyl]amino]-, ethyl ester (CA INDEX NAME)




RN 857068-26-9 CAPLUS

CN 3-Pyridinol, 2-[[6-[[4-[(2-hydroxyethyl)amino]-3-methylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




RN 857068-27-0 CAPLUS

CN 3-Pyridinol, 2-[[6-[[4-[(2-hydroxyethyl)amino]-3-methoxyphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)




RN 857068-28-1 CAPLUS

CN 3-Pyridinol, 2-[[6-[[4-[(4-hydroxybutyl)amino]-2-methylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)



RN 857068-29-2 CAPLUS


CN 3-Pyridinol, 2-[[6-[[4-[(2-hydroxyethyl)amino]-2,6-dimethylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-30-5 CAPLUS


CN 3-Pyridinol, 2-[[6-[[2,6-dimethyl-4-[[2-(4-morpholinyl)ethyl]amino]phenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)

PAGE 1-A







RN 857068-31-6 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[4-[[2-(dimethylamino)ethyl]amino]-2,6-dimethylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857068-32-7 CAPLUS  
 CN Benzoic acid, 2-[(2-hydroxyethyl)amino]-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-, ethyl ester (CA INDEX NAME)




RN 857068-33-8 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[[4-[(4-hydroxybutyl)amino]-2,6-dimethylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 857068-34-9 CAPLUS

CN 1-Propanesulfonamide, 3-[[4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3,5-dimethylphenyl]amino]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 857068-35-0 CAPLUS

CN 3-Pyridinol, 2-[[6-[[4-[[1-(hydroxymethyl)propyl]amino]-2,6-dimethylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:?) (CA INDEX NAME)






● x HCl


RN 857068-36-1 CAPLUS

CN Propanamide, 3-[[4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2,5-dimethylphenyl]amino]- (CA INDEX NAME)




RN 857068-37-2 CAPLUS

CN 3-Pyridinol, 2-[[6-[[4-[(2-hydroxyethyl)amino]-2,5-dimethylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-38-3 CAPLUS


CN 3-Pyridinol, 2-[[6-[[1-ethyl-5-[(2-hydroxyethyl)amino]-1H-pyrazol-4-yl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-39-4 CAPLUS  
 CN 3-Pyridinol, 2-[[6-[(2,3-dihydro-6-methyl-1H-indol-1-yl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857068-40-7 CAPLUS  
 CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-41-8 CAPLUS  
 CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857068-42-9 CAPLUS

CN 3-Pyridinol, 2-[[5,7-dimethyl-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-43-0 CAPLUS

CN 1H-Benzimidazole-6-carboxamide, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-N-[2-(3-hydroxypropyl)-5-methylphenyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857068-44-1 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-N-(3-methylphenyl)-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857068-45-2 CAPLUS

CN 1H-Benzimidazole-6-carboxamide, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-N-(3-methylphenyl)-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857068-46-3 CAPLUS

CN 1H-Benzimidazole-6-carboxamide, N-(3,5-dimethylphenyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857068-57-6 CAPLUS


CN 4-Morpholineethanol, α-[[[6-[[3,5-dimethylphenyl]amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]- (CA INDEX NAME)



RN 857068-58-7 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-6-[[3,5-dimethylphenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 857068-59-8 CAPLUS


CN 3-Pyridinol, 2-[[2-[[3-[(2R,6R)-2,6-dimethyl-4-morpholinyl]propyl]amino]-6-[[3,5-dimethylphenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 857068-60-1 CAPLUS


CN 3-Pyridinol, 2-[[6-[[3,5-dimethylphenyl]amino]methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857068-62-3 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-1H-


benzimidazol-1-yl)methyl]- (CA INDEX NAME)



RN 857068-63-4 CAPLUS


CN 1H-Benzimidazole-6-methanol, 2-[[3-[(2R,6R)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 857068-64-5 CAPLUS

CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-hydroxy-3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl)methyl]amino]-, hydrochloride (1:4) (CA INDEX NAME)




RN 857068-65-6 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-[[3-(4-thiomorpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-  
(CA INDEX NAME)



RN 857068-66-7 CAPLUS


CN 4-Morpholineethanol,  $\alpha$ -[[[6-[[[(3-bromophenyl)(2-hydroxyethyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 857068-67-8 CAPLUS

CN 2-Morpholineethanol, 4-[3-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]-  
(CA INDEX NAME)




RN 857068-68-9 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-thiomorpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857068-70-3 CAPLUS

CN 2-Morpholineethanol, 4-[3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]propyl]- (CA INDEX NAME)



RN 857068-71-4 CAPLUS


CN 2-Morpholineacetamide, 4-[3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]propyl]- (CA INDEX NAME)



RN 857068-72-5 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)






RN 857068-81-6 CAPLUS

CN Benzonitrile, 4-(2-hydroxyethyl)-3-[[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-88-3 CAPLUS

CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-94-1 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(3-hydroxypropyl)-5-(trifluoromethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857068-97-4 CAPLUS

CN Benzenepropanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-methyl- (CA INDEX NAME)




RN 857068-98-5 CAPLUS

CN Benzenepropanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-methyl- (CA INDEX NAME)




RN 857069-06-8 CAPLUS

CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-17-1 CAPLUS

CN Benzenepropanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-18-2 CAPLUS

CN Ethanol, 2-[(3,5-dimethylphenyl)[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-25-1 CAPLUS


CN Benzeneethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-6-methyl- (CA INDEX NAME)




RN 857069-26-2 CAPLUS  
 CN Butanamide, 4-[[[1-[(3,5-dimethylphenyl)[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857069-29-5 CAPLUS  
 CN Benzeneethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-37-5 CAPLUS  
 CN Butanamide, 4-[[[1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-38-6 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(2,5-dimethylphenyl)-1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857069-41-1 CAPLUS

CN Benzenepropanamide, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-43-3 CAPLUS

CN Benzenepropanol, 2-[[[1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-methyl- (CA INDEX NAME)




RN 857069-44-4 CAPLUS

CN 1H-Benzimidazole-6-methanamine, 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-N-[2-[2-(4-morpholinyl)ethyl]phenyl]-2-[[3-(4-morpholinyl)propyl]amino]-(CA INDEX NAME)






RN 857069-47-7 CAPLUS


CN 1H-Benzimidazole-6-methanamine, N-(3,5-dimethylphenyl)-1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-(CA INDEX NAME)



RN 857069-48-8 CAPLUS

CN Benzenesulfonamide, 4-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-(CA INDEX NAME)






● x HCl


RN 857069-55-7 CAPLUS

CN Benzenemethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857069-56-8 CAPLUS


CN Benzenemethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-5-methyl- (CA INDEX NAME)



RN 857069-57-9 CAPLUS


CN Ethanol, 2-[(3,5-dimethylphenyl)[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)






RN 857069-75-1 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(3-bromophenyl)-1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857069-76-2 CAPLUS

CN Benzenemethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-6-methyl- (CA INDEX NAME)




RN 857069-79-5 CAPLUS

CN 3-Pyridinol, 2-[[[5-[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857069-80-8 CAPLUS

CN Benzamide, 4-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-81-9 CAPLUS

CN Benzamide, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-83-1 CAPLUS

CN Benzonitrile, 3-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-84-2 CAPLUS

CN Benzeneethanol, 3-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-91-1 CAPLUS

CN 1H-Benzimidazole-6-methanamine, 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-N-(3-methylphenyl)-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857069-97-7 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[[3-(2-methoxyethoxy)-6-methyl-2-pyridinyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-00-9 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(2,5-dimethylphenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-04-3 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(hydroxymethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857070-09-8 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[[[3-(2-methoxyethoxy)-6-methyl-2-pyridinyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-10-1 CAPLUS


CN Benzeneethanol, 2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)





CN 1H-Benzimidazole-6-methanamine, N-(3,5-dimethylphenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



CN Benzeneethanol, 2-methyl-6-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)





CN 1H-Benzimidazole-6-methanamine, N-(3-methylphenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-18-9 CAPLUS

CN Benzenepropanamide, 2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)





RN 857070-19-0 CAPLUS

CN Benzonitrile, 3-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857070-20-3 CAPLUS

CN Benzenesulfonamide, 4-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857070-21-4 CAPLUS


CN 1H-Benzimidazole-6-methanamine, N-(3,5-dichlorophenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-22-5 CAPLUS  
 CN 1H-Benzimidazole-6-methanamine, 1-[(6-methyl-2-pyridinyl)methyl]-N-[2-[2-(4-morpholinyl)ethyl]phenyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857070-24-7 CAPLUS  
 CN Benzenemethanol, 2-methyl-6-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857070-25-8 CAPLUS  
 CN Benzenepropanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]amino]-4-methyl- (CA INDEX NAME)





RN 857070-27-0 CAPLUS  
 CN Benzenepropanol, 4-methyl-2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]amino]- (CA INDEX NAME)







RN 857070-29-2 CAPLUS

CN Benzamide, 4-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857070-30-5 CAPLUS



CN Benzeneethanol, 3-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857070-34-9 CAPLUS



CN Benzamide, 2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)

NAME)





RN 857070-40-7 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-41-8 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-43-0 CAPLUS

CN Benzenepropanol, 2-[[[1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]amino]-4-methyl- (CA INDEX NAME)





RN 857070-59-8 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(3-bromophenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-60-1 CAPLUS

CN Benzenemethanol, 2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857070-61-2 CAPLUS

CN Benzenemethanol, 5-methyl-2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857071-23-9 CAPLUS

CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-hydroxy-3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857083-26-2 CAPLUS


CN 3-Pyridinol, 2-[[[5-[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857083-27-3 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-[(2R,6R)-2,6-dimethyl-4-morpholinyl]propyl]amino]-5-[[3,5-dimethylphenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 857083-28-4 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-5-[[3,5-dimethylphenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 857083-29-5 CAPLUS


CN 1H-Benzimidazole-5-methanol, 2-[[3-[(2R,6R)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 857083-30-8 CAPLUS

CN 1H-Benzimidazole-5-methanol, 2-[[3-[2-(2-hydroxyethyl)-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




IT 857083-31-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of morpholine containing benzimidazoles as inhibitors of respiratory syncytial virus replication)

RN 857083-31-9 CAPLUS


CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-thiomorpholinyl)propyl]amino]- (CA INDEX NAME)




IT 857071-96-6  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of morpholine containing benzimidazoles as inhibitors of  
 respiratory syncytial virus replication)  
 RN 857071-96-6 CAPLUS  
 CN Carbamic acid, [2-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-  
 pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-  
 yl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 857070-63-4P 857070-64-5P 857070-65-6P  
 857070-68-9P 857070-83-8P 857070-84-9P  
 857070-99-6P 857071-00-2P 857071-01-3P  
 857071-02-4P 857071-03-5P 857071-04-6P  
 857071-05-7P 857071-08-0P 857071-09-1P  
 857071-11-5P 857071-13-7P 857071-15-9P  
 857071-17-1P 857071-19-3P 857071-29-5P  
 857071-32-0P 857071-34-2P 857071-43-3P  
 857071-46-6P 857071-48-8P 857071-58-0P  
 857071-60-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of morpholine containing benzimidazoles as inhibitors of  
 respiratory syncytial virus replication)  
 RN 857070-63-4 CAPLUS  
 CN 1H-Benzimidazole-6-carboxylic acid,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-  
 morpholinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)



RN 857070-64-5 CAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-  
 morpholinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)




RN 857070-65-6 CAPLUS  
 CN 1H-Benzimidazole-6-carboxaldehyde,  
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-  
 morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-68-9 CAPLUS  
 CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-  
 benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:4) (CA INDEX NAME)






● 4 HCl

RN 857070-83-8 CAPLUS  
 CN 3-Pyridinol, 6-methyl-2-[[6-[[[5-methyl-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-propyn-1-yl]phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857070-84-9 CAPLUS  
 CN 2-Propenenitrile, 3-[4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 857070-99-6 CAPLUS  
 CN 1H-Benzimidazole-6-carboxaldehyde, 2-[[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 857071-00-2 CAPLUS

CN 4-Morpholineethanol,  $\alpha$ -[[[6-(hydroxymethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]- (CA INDEX NAME)




RN 857071-01-3 CAPLUS

CN 4-Morpholineethanol,  $\alpha$ -[[[5-(hydroxymethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]- (CA INDEX NAME)




RN 857071-02-4 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-hydroxy-3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857071-03-5 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]- (CA INDEX NAME)




RN 857071-04-6 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]- (CA INDEX NAME)




RN 857071-05-7 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]- (CA INDEX NAME)




RN 857071-08-0 CAPLUS

CN 2-Morpholineacetic acid, 4-[3-[[6-(hydroxymethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]-, ethyl ester (CA INDEX NAME)




RN 857071-09-1 CAPLUS

CN 2-Morpholineacetic acid, 4-[3-[[5-(hydroxymethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]-, ethyl ester (CA INDEX NAME)



RN 857071-11-5 CAPLUS


CN 2-Morpholineacetic acid, 4-[3-[[6-(chloromethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 857071-13-7 CAPLUS

CN 2-Morpholineacetic acid, 4-[3-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]-, ethyl ester (CA INDEX NAME)




RN 857071-15-9 CAPLUS

CN 2-Morpholineacetic acid, 4-[3-[[4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]amino]propyl]-, ethyl ester (CA INDEX NAME)




RN 857071-17-1 CAPLUS

CN 2-Morpholineacetamide, 4-[3-[[4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]amino]propyl]- (CA INDEX NAME)



RN 857071-19-3 CAPLUS



CN 4-Morpholineethanol, α-[[[6-(chloromethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl



RN 857071-29-5 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857071-32-0 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857071-34-2 CAPLUS



CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl



RN 857071-43-3 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857071-46-6 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857071-48-8 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 1-[(6-bromo-2-pyridinyl)methyl]-6-(chloromethyl)-  
 N-[3-(4-morpholinyl)propyl]-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 857071-58-0 CAPLUS  
 CN 1H-Benzimidazole-6-carboxaldehyde,  
 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-  
 morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857071-60-4 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 6-(chloromethyl)-1-[(3-methoxy-6-methyl-2-  
 pyridinyl)methyl]-N-[3-(4-morpholinyl)propyl]-, hydrochloride (1:4) (CA  
 INDEX NAME)





● 4 HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:564654 CAPLUS

DOCUMENT NUMBER: 143:97359

TITLE: Preparation of amino-benzimidazoles as inhibitors of respiratory syncytial virus replication

INVENTOR(S): Bonfanti, Jean-Francois; Andries, Koenraad Jozef Lodewijk; Janssens, Frans Eduard; Sommen, Francois Maria; Guillemont, Jerome Emile Georges; Lacrampe, Jean Fernand Armand

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058870	A1	20050630	WO 2004-EP53617	20041220
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004298458	A1	20050630	AU 2004-298458	20041220
CA 2548666	A1	20050630	CA 2004-2548666	20041220
EP 1711485	A1	20061018	EP 2004-804953	20041220
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
CN 1894236	A	20070110	CN 2004-80037281	20041220
BR 2004017808	A	20070410	BR 2004-17808	20041220
JP 2007514718	T	20070607	JP 2006-544464	20041220
RU 2332414	C2	20080827	RU 2006-125729	20041220
IN 2006DN02972	A	20070824	IN 2006-DN2972	20060524
US 20090036466	A1	20090205	US 2006-596500	20060615

MX 2006007110  
 KR 2006118568  
 PRIORITY APPLN. INFO.:


A 20060823  
 A 20061123

MX 2006-7110 20060619  
 KR 2006-713072 20060629  
 EP 2003-104804 A 20031218  
 US 2004-567181P P 20040430  
 WO 2004-EP53617 W 20041220

OTHER SOURCE(S): CASREACT 143:97359; MARPAT 143:97359  
 GI



I



II

AB The title compds. [I; Q = Ar2, cycloalkyl or (un)substituted alkyl; G = a direct bond or (un)substituted alkanediyl; R1 = Ar1 or a monocyclic or bicyclic heterocycle; one of R2a and R3a = alkyl and the other one of R2a and R3a = H; in case R2a is different from hydrogen then R2b = H or alkyl, and R3b = H; in case R3a is different from hydrogen then R3b = H or alkyl, and R2b = H; or R2a, R2b, R3a and R3b all = H; R5 = H, alkyl; Ar1, Ar2 = (un)substituted Ph; and their prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochem. isomeric forms] having inhibitory activity on the replication of the respiratory syncytial virus, were prepared E.g., a multi-step synthesis of II, starting from (3-benzyloxy-6-methylpyridin-2-yl)methanol, was given. The exemplified compds. I were tested for activity against RSV (data given). The invention further concerns preparation of compds. I and compns. comprising them, as well as their use as a medicine.


IT 856895-07-3P 856895-14-2P 856895-16-4P  
 856895-18-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of amino-benzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 856895-07-3 CAPLUS

CN  $\beta$ -Alanine, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]-, ethyl ester (CA INDEX NAME)




RN 856895-14-2 CAPLUS


CN Benzonitrile, 4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)



RN 856895-16-4 CAPLUS  
 CN 2-Pyrrolidinone, 1-[3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]propyl]- (CA INDEX NAME)



RN 856895-18-6 CAPLUS  
 CN 3-Pyridinol, 2-[[2-[[4-(2-aminoethyl)phenyl]amino]-5,7-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



IT 856894-96-7P 856894-97-8P 856894-98-9P  
 856894-99-0P 856895-00-6P 856895-01-7P  
 856895-02-8P 856895-03-9P 856895-04-0P  
 856895-05-1P 856895-06-2P 856895-08-4P  
 856895-09-5P 856895-10-8P 856895-11-9P  
 856895-12-0P 856895-13-1P 856895-15-3P  
 856895-17-5P 856895-19-7P 856895-20-0P  
 856895-21-1P 856895-22-2P 856895-23-3P  
 856895-24-4P 856895-25-5P 856895-26-6P  
 856895-27-7P 856895-28-8P 856895-29-9P  
 856895-30-2P 856895-31-3P 856895-32-4P  
 856895-33-5P 856895-34-6P 856895-35-7P

856895-36-8P 856895-37-9P 856895-38-0P


856895-44-8P 856895-45-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino-benzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 856894-96-7 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(1-piperidiny)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856894-97-8 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(1-pyrrolidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856894-98-9 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856894-99-0 CAPLUS

CN 1,2-Propanediol, 3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 856895-00-6 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-01-7 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[2-(1-piperidinyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-02-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-hydroxypropyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-03-9 CAPLUS


CN Propanamide, 3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 856895-04-0 CAPLUS  
 CN 3-Pyridinol, 2-[[2-[[4-(aminomethyl)phenyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-05-1 CAPLUS  
 CN 3-Pyridinol, 2-[[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-06-2 CAPLUS  
 CN 3-Pyridinol, 2-[[2-[[2-(1H-imidazol-5-yl)ethyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-08-4 CAPLUS  
 CN 3-Pyridinol, 2-[[2-[[4-(2-aminoethyl)phenyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-09-5 CAPLUS  
 CN 3-Pyridinol, 2-[[2-[(4-aminophenyl)amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 856895-10-8 CAPLUS  
 CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[(2-pyridinylmethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-11-9 CAPLUS  
 CN 3-Pyridinol, 2-[[2-[(3-methoxypropyl)amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-12-0 CAPLUS

CN 3-Pyridinol, 2-[[2-(cyclohexylamino)-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-13-1 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[(2-phenylethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 856895-15-3 CAPLUS


CN 3-Pyridinol, 2-[[2-[[2-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-17-5 CAPLUS

CN Benzenesulfonamide, 4-[2-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]ethyl]- (CA INDEX NAME)







RN 856895-19-7 CAPLUS  
 CN 3-Pyridinol, 2-[[2-[(cyclohexylmethyl)amino]-5,7-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 856895-20-0 CAPLUS  
 CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(1-piperidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 856895-21-1 CAPLUS  
 CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 856895-22-2 CAPLUS

CN 1,2-Propanediol, 3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 856895-23-3 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(1-pyrrolidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 856895-24-4 CAPLUS

CN 3-Pyridinol, 2-[[2-[[2-(4-methoxyphenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-25-5 CAPLUS

CN 3-Pyridinol, 2-[[2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-26-6 CAPLUS

CN 3-Pyridinol, 2-[[2-[(5-hydroxypentyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-27-7 CAPLUS

CN 3-Pyridinol, 2-[[2-[(3-hydroxypropyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-28-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[(6-hydroxyhexyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-29-9 CAPLUS

CN 3-Pyridinol, 2-[[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-30-2 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]- (CA INDEX NAME)




RN 856895-31-3 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(methylthio)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 856895-32-4 CAPLUS

CN Butanoic acid, 4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]-, ethyl ester (CA INDEX NAME)




RN 856895-33-5 CAPLUS


CN Butanamide, 4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 856895-34-6 CAPLUS  
 CN 3-Pyridinol, 2-[[2-[[2-(1H-indol-3-yl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 856895-35-7 CAPLUS  
 CN 3-Pyridinol, 6-methyl-2-[[2-[[2-(2-pyridinyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 856895-36-8 CAPLUS  
 CN 3-Pyridinol, 2-[[2-[[2-(3-fluorophenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-37-9 CAPLUS

CN 3-Pyridinol, 2-[[2-[[2-(4-fluorophenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-38-0 CAPLUS

CN 3-Pyridinol, 2-[[2-[[2-(2-hydroxyethoxy)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 856895-44-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[[4-(2-aminoethyl)phenyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl


RN 856895-45-9 CAPLUS

CN 3-Pyridinol, 2-[[2-[[4-(2-aminoethyl)phenyl]amino]-5,7-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 856895-18-6


CMF C24 H27 N5 O



CM 2

CRN 64-19-7

CMF C2 H4 O2




IT 856895-40-4P 856895-41-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino-benzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 856895-40-4 CAPLUS

CN 1H-Benzimidazol-2-amine, 4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 856895-41-5 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:117213 CAPLUS

DOCUMENT NUMBER: 140:163868

TITLE: Preparation of acylaminoheteroarenes as upregulators of endothelial nitric oxide synthase (eNOS).

INVENTOR(S): Strobel, Hartmut; Wohlfart, Paulus; Below, Peter

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: Eur. Pat. Appl., 40 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1388341	A1	20040211	EP 2002-17585	20020807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2494298	A1	20040219	CA 2003-2494298	20030724
WO 2004014369	A1	20040219	WO 2003-EP8102	20030724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003260325	A1	20040225	AU 2003-260325	20030724
EP 1534275	A1	20050601	EP 2003-784054	20030724
EP 1534275	B1	20080312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013294	A	20050712	BR 2003-13294	20030724
JP 2005538123	T	20051215	JP 2004-526764	20030724
AT 388702	T	20080315	AT 2003-784054	20030724
US 20040110808	A1	20040610	US 2003-634979	20030805
US 7338956	B2	20080304		
MX 2005000697	A	20050408	MX 2005-697	20050117
PRIORITY APPLN. INFO.:			EP 2002-17585	A 20020807



US 2002-432314P


P 20021210

WO 2003-EP8102

W 20030724

OTHER SOURCE(S):  
GI

MARPAT 140:163868



AB Title compds. [I; R1, R4 = H, (substituted) alkyl, alkenyl, alkynyl, Ph, heteroaryl; R2, R3 = H, OH, halo, cyano, alkoxy, PhO, (substituted) alkyl, PhCONH, etc.; R5 = (substituted) aryl, heteroaryl; X = NR30, S, O, CH:CH, N:CH; R30 = H, (substituted) alkyl, alkenyl, alkynyl], were prepared Thus, title compound I (R1-R4 = H; R5 = 4-FC6H4; X = NH) (preparation outlined) activated eNOS transcription with EC50 = 0.028  $\mu$ M.


IT 656250-85-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylaminoheteroarenes as upregulators of endothelial nitric oxide synthase)

RN 656250-85-0 CAPLUS

CN Benzamide, 4-fluoro-N-[1-[2-(2-pyridinyl)ethyl]-5-(trifluoromethyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:363331 CAPLUS

DOCUMENT NUMBER: 137:93712

TITLE: Rapid Microwave-Assisted Liquid-Phase Combinatorial Synthesis of 2-(Arylamino)benzimidazoles

AUTHOR(S): Bendale, Pravin M.; Sun, Chung-Ming

CORPORATE SOURCE: Department of Chemistry, National Dong Hwa University, Hualien, 974, Taiwan

SOURCE: Journal of Combinatorial Chemistry (2002), 4(4), 359-361

CODEN: JCCHFF; ISSN: 1520-4766

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:93712


AB An efficient, facile, and practical liquid-phase combinatorial synthesis of

benzimidazoles under microwave irradiation is described. In the first step, polymer-bound activated aryl fluoride was condensed with selective primary amines via an ipso-fluoro displacement reaction. Reduction of the polymer-bound nitro group followed by cyclization with isothiocyanates afforded immobilized benzimidazoles. The desired products were obtained in high yield with high purity after detaching from the soluble matrix. All reactions involved (S<sub>N</sub>Ar reaction, reduction, cyclization, and support cleavage) were performed completely within a few minutes under microwave irradiation. The coupling of microwave technol. with liquid-phase combinatorial synthesis constitutes a novel and particularly attractive avenue for the rapid generation of structurally diverse libraries.

IT 442129-64-8P 442129-68-2P  
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)  
 (rapid microwave-assisted liquid-phase combinatorial synthesis of 2-(arylamino)benzimidazoles)  
 RN 442129-64-8 CAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-(phenylamino)-1-[2-(2-pyridinyl)ethyl]-, methyl ester (CA INDEX NAME)



RN 442129-68-2 CAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(4-fluorophenyl)amino]-1-[2-(2-pyridinyl)ethyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:97991 CAPLUS  
 DOCUMENT NUMBER: 137:93711  
 TITLE: Soluble polymer-supported synthesis of 2-(arylamino)benzimidazoles  
 AUTHOR(S): Wu, Cheng-Yi; Sun, Chung-Ming  
 CORPORATE SOURCE: Department of Chemistry, National Dong Hwa University, Shou-Feng, Hualien, 974, Taiwan  
 SOURCE: Tetrahedron Letters (2002), 43(8), 1529-1533  
 CODEN: TELEAY; ISSN: 0040-4039  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 137:93711

AB A novel liquid-phase method for the construction of biol. important benzimidazoles has been developed. A library of N-substituted 2-aminobenzimidazoles was readily assembled utilizing SNAr reactions, reduction of the nitro group, and a one-pot cyclization with isothiocyanate as the key step in the synthesis. The crude benzimidazoles were obtained in 80-99% yields with 78-95% HPLC purity.

IT 442129-64-8P 442129-68-2P 442129-73-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (soluble polymer-supported synthesis of (arylamino)benzimidazoles)


RN 442129-64-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid,  
 2-(phenylamino)-1-[2-(2-pyridinyl)ethyl]-, methyl ester (CA INDEX NAME)




RN 442129-68-2 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid,  
 2-[(4-fluorophenyl)amino]-1-[2-(2-pyridinyl)ethyl]-, methyl ester (CA INDEX NAME)



RN 442129-73-9 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid,  
 2-[(3-methylphenyl)amino]-1-[2-(2-pyridinyl)ethyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:12444 CAPLUS  
 DOCUMENT NUMBER: 134:86248

TITLE: Preparation of benzimidazoles as respiratory syncytial virus replication inhibitors.

INVENTOR(S): Janssens, Frans Eduard; Meersman, Kathleen Petrus Marie-Jose; Sommen, Francois Maria; Guillemont, Jerome Emile Georges; Lacrampe, Jean Fernand Armand; Andries, Koenraad Jozef Lodewijk Marcel

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 119 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000611	A1	20010104	WO 2000-EP5676	20000620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2376781	A1	20010104	CA 2000-2376781	20000620
BR 2000012054	A	20020319	BR 2000-12054	20000620
EP 1196408	A1	20020417	EP 2000-943841	20000620
EP 1196408	B1	20040915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103804	T2	20020521	TR 2001-3804	20000620
HU 2002001723	A2	20021128	HU 2002-1723	20000620
HU 2002001723	A3	20040428		
JP 2003503401	T	20030128	JP 2001-507020	20000620
EE 200100692	A	20030217	EE 2001-692	20000620
EE 4590	B1	20060215		
NZ 515418	A	20031128	NZ 2000-515418	20000620
EP 1418175	A1	20040512	EP 2004-100543	20000620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, MK, CY, AL				
AT 276244	T	20041015	AT 2000-943841	20000620
AU 779516	B2	20050127	AU 2000-58167	20000620
PT 1196408	T	20050131	PT 2000-943841	20000620
ES 2228559	T3	20050416	ES 2000-943841	20000620
CN 1239496	C	20060201	CN 2000-809619	20000620
AP 1552	A	20060228	AP 2002-2397	20000620
W: GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZM, ZW				
SG 122814	A1	20060629	SG 2004-362	20000620
TR 200600172	T1	20070122	TR 2006-172	20000620
PL 198021	B1	20080530	PL 2000-362890	20000620
TW 248932	B	20060211	TW 2000-89112477	20000626
EG 24026	A	20080326	EG 2000-833	20000627
IN 2001MN01539	A	20050304	IN 2001-MN1539	20011206
MX 2002000112	A	20020702	MX 2002-112	20011219
HR 2001000933	A1	20030630	HR 2001-933	20011219
ZA 2001010478	A	20030320	ZA 2001-10478	20011220
NO 2001006368	A	20020228	NO 2001-6368	20011227
NO 324036	B1	20070730		
US 6924287	B1	20050802	US 2001-30202	20011227
BG 106287	A	20021031	BG 2002-106287	20020108

BG 65372	B1	20080430		
HK 1046141	A1	20060922	HK 2002-107761	20021025
US 20050234047	A1	20051020	US 2005-144103	20050603
US 7173054	B2	20070206		
US 20050239771	A1	20051027	US 2005-144126	20050603
US 7173034	B2	20070206		
US 20060154913	A1	20060713	US 2006-332557	20060112
US 7361657	B2	20080422		
US 20070021410	A1	20070125	US 2006-519719	20060911
US 7390811	B2	20080624		

PRIORITY APPLN. INFO.:

EP 1999-202087	A	19990628
EP 2000-200452	A	20000211
EP 2000-943841	A3	20000620
WO 2000-EP5676	W	20000620
US 2001-30202	A3	20011227
US 2005-144103	A3	20050603

OTHER SOURCE(S): MARPAT 134:86248  
GI



AB Use of title compds. [I; a1:a2a3:a4 = (substituted) CH:CHCH:CH, N:CHCH:CH, CH:N:CH:CH, CH:CHN:CH, CH:CHCH:N; Q = R2R4NAX1, R2R4NCOAX1, specified (heterocyclic) ring, etc.; A = alkylene; R2 = H, CHO, alkylcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, aminocycloalkyl, etc.; R4 = H, alkyl, aralkyl; G = bond, alkanediyl; R1 = (substituted) piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, etc.] for treatment of viral infection is claimed. Thus, 1,1-dimethylethyl 4-[[1-[[3,5-dihydro-3,3-dimethyl-9-(phenylmethoxy)-1H-1,3-dioxepino[5,6-c]pyridin-2-yl]methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate was refluxed 6 h in 10N HCl to give 4-[[1-[[3,5-dihydro-3,3-dimethyl-9-(phenylmethoxy)-1H-1,3-dioxepino[5,6-c]pyridin-2-yl]methyl]-1H-benzimidazol-2-yl]amino]piperidine. Tested I inhibited respiratory syncytial virus replication with IC50 = 0.00013-2.5119  $\mu$ M.


IT 1100824-97-2 1100824-98-3 1100824-99-4  
1100825-01-1 1100825-48-6

RL: PRPH (Prophetic)

(Preparation of benzimidazoles as respiratory syncytial virus replication inhibitors.)


RN 1100824-97-2 CAPLUS

CN 1,3-Propanediamine, N1-[1-[(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]-, hydrochloride (1:5) (CA INDEX NAME)



●5 HCl


RN 1100824-98-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



●4 HCl

● H<sub>2</sub>O


RN 1100824-99-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



● 4 HCl

● H<sub>2</sub>O


RN 1100825-01-1 CAPLUS  
 CN 1,3-Propanediamine, N1-[1-[(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]-2-(phenylmethoxy)-, hydrochloride, hydrate (1:3:1) (CA INDEX NAME)



● 3 HCl

● H<sub>2</sub>O

RN 1100825-48-6 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED



IT 317846-15-4P 317846-16-5P 317846-37-0P

317846-94-9P 317846-95-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazoles as respiratory syncytial virus replication inhibitors)

RN 317846-15-4 CAPLUS

CN Acetamide, N-[2-[[[cis-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]cyclohexyl]amino]ethyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 317846-16-5 CAPLUS

CN Acetamide, N-[2-[[[trans-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]cyclohexyl]amino]ethyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 317846-37-0 CAPLUS

CN 3-Pyridinol, 2-[[2-[(3-amino-2-hydroxypropyl)amino]-1H-benzimidazol-1-




yl)methyl]-6-methyl- (CA INDEX NAME)



RN 317846-94-9 CAPLUS

CN 1,4-Cyclohexanediamine, N1-(2-aminoethyl)-N4-[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]-, hydrochloride (1:4), trans- (CA INDEX NAME)


Relative stereochemistry.



● 4 HCl

RN 317846-95-0 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[[1-(2-aminoethyl)-3-piperidinyl]methyl]-1-(2-pyridinylmethyl)-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl


IT 317847-82-8

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of benzimidazoles as respiratory syncytial virus replication inhibitors)

RN 317847-82-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-[bis(phenylmethyl)amino]-2-(phenylmethoxy)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 317847-49-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of benzimidazoles as respiratory syncytial virus replication  
 inhibitors)  
 RN 317847-49-7 CAPLUS  
 CN Cyclohexanone, 4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]- (CA  
 INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:752271 CAPLUS  
 DOCUMENT NUMBER: 123:339888  
 ORIGINAL REFERENCE NO.: 123:61003a, 61006a  
 TITLE: N-(1-Phenyl-2-benzimidazolyl)-N'-phenylurea  
 derivatives as potent inhibitors of  
 acyl-CoA:cholesterol acyltransferase (ACAT)  
 AUTHOR(S): Kumazawa, Toshiaki; Harakawa, Hiroyuki; Fukui, Hiromi;  
 Shirakura, Shiro; Ohishi, Eiko; Yamada, Koji  
 CORPORATE SOURCE: Pharm. Res. Lab., Kyowa Hakko Kogyo Co., Ltd.,  
 Shizuoka, 411, Japan  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995),  
 5(16), 1829-32  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB N-(1-phenyl-2-benzimidazolyl)-N'-phenylurea derivs., e.g., I, were prepared as ACAT inhibitors. These compds. showed potent ACAT inhibitory activity in vitro (liver microsomes from cholesterol-fed rabbits) and hypocholesterolemic activity in vivo (cholesterol-fed golden hamsters).

IT 170752-07-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of (phenylbenzimidazolyl)phenylureas as potent inhibitors of ACAT)


RN 170752-07-5 CAPLUS

CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(3-chloro-2-pyridinyl)-1H-benzimidazol-2-yl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 170752-06-4


CMF C25 H26 Cl N5 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L6 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:709095 CAPLUS

DOCUMENT NUMBER: 123:218414

ORIGINAL REFERENCE NO.: 123:38595a,38598a

TITLE: Imidazoles and antiarteriosclerotics containing the imidazoles

INVENTOR(S): Kumazawa, Toshiaki; Harakawa, Hiroyuki; Fukui, Hiromi; Shirokura, Shiro; Ooishi, Eiko; Yamada, Koji

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Kk, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07133224	A	19950523	JP 1993-280961	19931110
PRIORITY APPLN. INFO.:			JP 1993-280961	19931110
OTHER SOURCE(S):	MARPAT	123:218414		
GI				




I

AB Antiarteriosclerotics contain imidazoles I [X, Y = CH, N; Z = single bond, CH<sub>2</sub>; R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> = H, halo, lower alkyl, OH, lower alkoxy, carboxy, lower alkoxy-carbonyl, NH<sub>2</sub>, mono- or di-lower alkyl-substituted amino, carbamoyl, mono- or di-lower alkyl-substituted carbamoyl, CF<sub>3</sub>; R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> = H, halo, lower alkyl, lower alkoxy; R<sub>7</sub> = H, lower alkyl, lower alkyl-(un)substituted cycloalkyl] or their pharmacol. acceptable salts as active ingredients. N-[1-(2-chlorophenyl)-2-benzimidazolyl]-N'-(2,6-diisopropylphenyl)urea (II) (2.3 g) was prepared by treatment of 1.5 g 2-amino-1-(2-chlorophenyl)benzimidazole and 1.46 mL 2,6-diisopropylphenyl isocyanate. II (at 10<sup>-7</sup>M) inhibited acyl CoA:cholesterol acyltransferase by 85%. II showed min. LD of >100 mg/kg i.p. in mice. A formulation example of tablets is given.

IT 168120-34-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (antiarteriosclerotics containing imidazoles)

RN 168120-34-1 CAPLUS

CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(4-methyl-2-pyridinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



=> fil stnguide  
 COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST	ENTRY	SESSION
	94.48	281.54
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-13.12	-13.12

FILE 'STNGUIDE' ENTERED AT 09:11:55 ON 12 FEB 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Feb 6, 2009 (20090206/UP).

=>

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.03	283.57
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-13.12

STN INTERNATIONAL LOGOFF AT 09:29:18 ON 12 FEB 2009